- Home
- PPLI vs IMNM Comparison
PPLI vs IMNM Comparison
Compare PPLI & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PPLI | IMNM |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.5B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PPLI | IMNM |
|---|---|---|
| Price | $38.66 | $18.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 17 |
| Target Price | ★ $56.80 | $35.19 |
| AVG Volume (30 Days) | 1.2M | ★ 1.4M |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.97 | 51.40 |
| EPS | ★ 5.65 | N/A |
| Revenue | ★ $4,365,235,000.00 | $6,941,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.70 | $18,803.97 |
| P/E Ratio | $7.01 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $35.38 | $14.64 |
| 52 Week High | $48.32 | $30.06 |
Technical Indicators
Market Signals| Indicator | PPLI | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 44.93 | 35.71 |
| Support Level | $37.56 | $17.83 |
| Resistance Level | $40.36 | $23.48 |
| Average True Range (ATR) | 1.03 | 0.98 |
| MACD | -0.22 | 0.14 |
| Stochastic Oscillator | 17.06 | 32.67 |
Price Performance
Historical ComparisonAbout PPLI People Incorporated Common Stock
People Inc is a media and publishing business that operates a portfolio of brands, including PEOPLE, Food & Wine, Travel + Leisure, InStyle, Better Homes & Gardens, and Southern Living. The company also holds a minority equity stake in MGM Resorts International.
About IMNM Immunome Inc.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.